 

Active ingredient: Azithromycin 

 

Form/Route: Suspension/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 
Design: Single-dose, two-way, crossover in-vivo 

Strength: 200 mg/5 ml 

Subjects: Normal healthy males and females, general population 

Additional Comments: 




______________________________________________________________________________ 

 

2. Type of study: Fed 
Design: Single-dose, two-way, crossover in-vivo 

Strength: 200 mg/5 ml 

Subjects: Normal healthy males and females, general population 

Additional comments: 




_____________________________________________________________________________ 

 

Analytes to measure: Azithromycin in plasma 

 

Bioequivalence based on (90% CI): Azithromycin 

 

Waiver request of in-vivo testing: 100 mg/5 ml based on (i) acceptable bioequivalence studies 
on the 200 mg/5 ml strength, (ii) acceptable dissolution testing across all strengths, and (iii) 
proportional similarity in the formulations across all strengths. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this 
product at this website. Please note that a dosage unit is based on the labeled concentration of the 
suspension product. Please use the dosage unit (5 ml). A total of 12 units from 12 different 
bottles should be used. Specifications will be determined upon review of the application. 

 


